Obbligazioni societarie HIGH YIELD e oltre, verso frontiere inesplorate - Vol. 2
- Creatore Discussione gionmorg
- Data di Inizio
Benvenuto tra noi @gualberto
iguanito
Forumer storico
Se non hanno il kid non possono operare.Dipende da loro non dal cliente
Fabrib
Forumer storico
The world's largest generic manufacturer Teva reports an increase in sales and a result that hit the market's expectations. The company also applied to increase the forecast for the full year.
Revenue amounted to $ 4.53 billion, compared with Bloomberg analyst consensus, which was 4.51.
Adjusted earnings per share was $ 0.68, which is 26 percent better than analyst consensus, which was 0.54.
Teva now estimates that earnings for the full year are in the range of $ 2.80-2.90 per share, an increase from previous forecasts which was between $ 2.55-2.80 dollars. The market, on average, yielded a profit of $ 2.77 and the expectations ranged from $ 2.67-2.93.
Revenue for the full year is expected to be between 18.6 and 19.0 billion dollars, a slight increase in the lower part of the range, as previous forecasts were 18.5-19.0 billion. On average, the market had expected earnings of $ 18.84 billions
US make-up manufacturer Avon reported sales higher than expected during the third quarter.
Turnover amounted to $ 1,346.3 million (1,378.2), compared with Factset analyst consensus of 1 167.
The adjusted gross margin was 57.1 percent. The expectation was 58.4 percent, according to Bloomberg's summary.
Earnings per share ended at $ 0.21. Adjusted earnings per share was 0.02 USD.
Revenue amounted to $ 4.53 billion, compared with Bloomberg analyst consensus, which was 4.51.
Adjusted earnings per share was $ 0.68, which is 26 percent better than analyst consensus, which was 0.54.
Teva now estimates that earnings for the full year are in the range of $ 2.80-2.90 per share, an increase from previous forecasts which was between $ 2.55-2.80 dollars. The market, on average, yielded a profit of $ 2.77 and the expectations ranged from $ 2.67-2.93.
Revenue for the full year is expected to be between 18.6 and 19.0 billion dollars, a slight increase in the lower part of the range, as previous forecasts were 18.5-19.0 billion. On average, the market had expected earnings of $ 18.84 billions
US make-up manufacturer Avon reported sales higher than expected during the third quarter.
Turnover amounted to $ 1,346.3 million (1,378.2), compared with Factset analyst consensus of 1 167.
The adjusted gross margin was 57.1 percent. The expectation was 58.4 percent, according to Bloomberg's summary.
Earnings per share ended at $ 0.21. Adjusted earnings per share was 0.02 USD.
impegnativo
Guest
iguanito
Forumer storico
A conferma di ciò ecco cosa mi ha risposto DB, avendo io fatto presente il problema e chiesto espressamente se il cliente professionale potesse operare in mancanza di kid:
"l’indisponibilità del KID blocca l’operatività sul titolo e tale blocco non è in alcun modo by-passabile dai nostri applicativi."
Maio72
Follow the white rabbit
Kid a parte. Vedo che sei long di brutto. Non temi di rimanere incastrato dal rialzo tassi?
iguanito
Forumer storico
Su alcune lo sono già. ma entro con poco e semmai incremento mediando al ribasso. Inoltre trattasi di emittenti che reputo sicure e poi son soldi che non mi servono nell'immediato. Mi interessa prendere le cedole perchè tanto prima o poi c'è sempre un ritorno verso la "qualità". In quel momento se mi conviene vendo. So attendere; del resto sono un "pischellino"
ginestra
Forumer attivo
a me hanno detto che avrebbero fatto richiesta all emittente a maggio 2018 ( parlo di tutte le perp di vw , bayer ecc ecc)
Genworth: We See Almost No Chance Of Regulatory Approval. This Deal Would Be A Disaster For Policyholders $GNW
https://seekingalpha.com/article/4216921
https://seekingalpha.com/article/4216921